Title

Measuring personal and functional changes in prostate cancer survivors: Development and validation of the FADE: Data from the TROG 03.04 RADAR trial

Date of this Version

2016

Document Type

Journal Article

Publication Details

Citation only

Bitsika, V., Sharpley, C. F., Christie, D. R. H., Bradford, R., Steigler, A., & Denham, J. W. (2016). Measuring personal and functional changes in prostate cancer survivors: Development and validation of the FADE: Data from the TROG 03.04 RADAR trial. Psycho-Oncology: Journal of the Psychological, Social and Behavioural Dimensions of Cancer.

Access the journal

Copyright © 2016 John Wiley & Sons, Ltd.

ISSN

1057-9249 print, 1099-1611 online

Abstract

Extract:

Background

There are more survivors of prostate cancer (PCa) than any other cancer [1]. Although there are a number of successful treatments for PCa such as prostatectomy, radiation therapy, hormone therapy or active surveillance (for men with low grade cancer that is monitored until there is evidence of need for curative treatment), there is evidence that each of these carries some adverse symptomatic side effects which last into ‘survivorship’, or at least 5 years post-diagnosis as defined by the American Cancer Society [2]. These symptomatic side effects have been investigated by measures such as the EORTC QLQ PR-25 and associated scales, the National Comprehensive Cancer Network’s Distress Thermometer Screening Tool and the Expanded Prostate Cancer Index Composite for Clinical Practice. Self-report scales that measure anxiety, depression and quality of life are also used when investigating the longer-term effects of PCa treatment upon survivors.

This document is currently not available here.

Share

COinS
 

This document has been peer reviewed.